文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌不同风险组的监测模式:真实世界分析

Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis.
PubMed 文献 · BJU Int · 2026-04-23

基于荷兰两项人群队列的真实世界数据,分析2791例原发和复发非肌层浸润性膀胱癌(NMIBC)的膀胱镜监测模式与指南推荐的依从性。低危组37.6%监测过密,高危组88.2%监测不足,中危组依从性从78.1%降至59.3%且异质性大。结论提示监测实践与推荐存在显著偏差,需优化监测方案。

要点

  • 低危NMIBC存在膀胱镜监测过度使用,首年人均1.3次(范围0-4)。
  • 高危NMIBC多数监测不足,88.2%低于推荐强度,但依从性随时间改善。
  • 中危NMIBC监测异质性大,依从性从78.1%降至59.3%,监测不足比例从21.7%升至39.8%。

核心结论

  • 真实世界中NMIBC监测实践与指南推荐存在显著偏差,低危过度监测、高危监测不足,中危监测异质性大。

研究设计与样本

  • 基于荷兰两项人群队列研究的真实世界数据分析,共纳入2791例原发和复发肿瘤,按低危、中危和(极高)高危分组比较膀胱镜监测模式与指南推荐。
  • 对204例有可用数据的肿瘤子集进行深入分析,评估症状发生及膀胱镜以外诊断手段(细胞学、影像、活检)的使用情况。

主要发现

  • 低危NMIBC中37.6%监测强度高于推荐,首年平均膀胱镜次数1.3次(范围0-4)。
  • 中危NMIBC总体依从推荐,但诊断后数年依从性从78.1%降至59.3%,监测不足比例从21.7%升至39.8%。
  • 高危NMIBC中88.2%监测低于推荐,但依从性随时间改善。
  • 204例深入分析显示细胞学使用随风险组升高(低危50.0%、中危52.3%、高危88.9%),影像(25-65%)和活检(25-85%)也较常用。
  • 约三分之一膀胱肿瘤随访期间报告症状,但症状似乎不影响监测模式。

临床怎么用

  • 临床应关注低危NMIBC膀胱镜监测过密问题,避免不必要的资源消耗和患者负担。
  • 高危NMIBC监测不足普遍,需加强依从性管理以确保推荐监测强度。
  • 中危NMIBC监测方案异质性大,应推动标准化以优化医疗资源分配。

局限性

  • 研究基于荷兰人群队列,结果外推需谨慎。
  • 症状与监测模式的分析仅基于204例有可用数据的肿瘤子集,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide insight into real-world surveillance practices for patients with low-risk (LR), intermediate-risk (IR), and (very) high-risk (HR) non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Cystoscopy surveillance patterns were analysed using real-world data from two population-based cohort studies in the Netherlands, comparing practices to guideline recommendations by risk group. As bladder cancer-related symptoms may prompt diagnostic investigations beyond routine follow-up, we evaluated the occurrence of such symptoms and the use of various diagnostics including cystoscopy in a subset of patients with available data. RESULTS: In total, 2791 primary and recurrent tumours were included in the analyses. Among patients with LR NMIBC, 37.6% were monitored more intensively than recommended. The average number of cystoscopies in the first follow-up year was 1.3 (range 0-4). IR NMIBCs were generally monitored in accordance with guideline recommendations. However, adherence declined over the years following diagnosis, dropping from 78.1% to 59.3%. The proportion of patients with IR NMIBCs who were monitored less than recommended increased from 21.7% to 39.8%. Most HR NMIBCs (88.2%) were monitored less than recommended, though adherence improved over time. In-depth analysis of 204 tumours revealed that next to cystoscopy, cytology was frequently employed, increasing with risk group (LR: 50.0%, IR: 52.3%, HR: 88.9%). Imaging (25-65%) and biopsies (25-85%) were also commonly performed. Surveillance patterns varied especially among IR NMIBCs. Symptoms were reported in approximately one third of bladder tumours during follow-up but did not appear to affect surveillance patterns. CONCLUSION: Our findings demonstrate substantial deviations from recommended NMIBC surveillance practices, with cystoscopy overuse in LR disease and underuse in HR cases. Surveillance of IR NMIBC was particularly heterogenous, using varying diagnostic investigations. These insights highlight the need to refine NMIBC surveillance schedules to improve patient outcomes and optimise healthcare resource allocation.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van Hoogstraten LMC, Vermeulen SH, Hof JP, et al. Surveillance patterns in non-muscle-invasive bladder cancer across risk groups: a real-world analysis. BJU Int. 2026. PMID: 42024120. doi:10.1111/bju.70297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。